

16638 U.S. PTO
010604

Attorney Docket No. 5702.240-US
Jeppesen et al.
Express Mail Label No. EV 246879475 US

Attorney Docket No.: 5702.240-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
EXPRESS MAIL CERTIFICATE**

22581 U.S. PTO
10/752343
010604

MS: Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Re: U.S. Patent Application for
Title: Compounds Useful in the Treatment of Conditions Mediated by
Peroxisome Proliferator-Activated Receptors (PPAR)
Applicants: Jeppesen et al.

Sir:

Express Mail Label No. EV 246879484 US

Date of Deposit: January 6, 2004

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application (96 pages of specification, 1 page of abstract,
0 sheets of drawings)
3. Executed Combined Declaration and Power of Attorney (from S/N
09/419,864)
4. Information Disclosure Statement
5. Form PTO-1449

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee"
under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for
Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Dolly Kapadia

(Name of person mailing paper(s) or fee)

Dolly Kapadia

(Signature of person mailing paper(s) or fee)

Mailing Address:

Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE

Attorney Docket No.: 5702.240-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILING UNDER 37 C.F.R. 1.53(b)

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Express Mail Label No. EV 246879484 US
Date of Deposit January 6, 2004

Sir:

This is a request for filing a **divisional** application under 37 C.F.R. 1.53(b) of U.S. application serial no. 09/419,864

Applicant(s): Jeppesen et al.

Title: Compounds Useful in the Treatment of Conditions Mediated by Peroxisome Proliferator-Activated Receptors (PPAR)

96 pages of specification 1 page of abstract

0 sheets of Formal Drawings

3 sheets of unexecuted Declaration and Power of Attorney

[x] The filing fee is calculated as follows:

Basic Fee: \$770.00

Total Claims: $54 - 20 = 34 \times 18 =$ \$612.00

Independent Claims: $1 - 3 = 0 \times 86 =$ \$0.00

Total Fee: \$1382.00

Priority of Danish application no. PA 1998 01356 filed on October 21, 1998 is claimed under 35 U.S.C. 119. A certified copy has been previously submitted.


Priority of U.S. provisional application no. 60/106,645 filed on November 2, 1998 is claimed under 35 U.S.C. 119.

The benefit of U.S. application serial no. 09/419,864 filed on October 19, 1999, now U.S. Patent no. 6,248,781, is claimed under 35 U.S.C. 120.

Address all future communications to Reza Green, Esq., Novo Nordisk Pharmaceuticals, Inc., 100 College Road West, Princeton, NJ 08540.

Please charge the required fee, estimated to be \$1382, with this application and credit any overpayments to Novo Nordisk Pharmaceuticals, Inc., Deposit Account No. 14-1447. Please charge any additional fees, should they be required, to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,



Rosemarie R. Wilk-Orescan, Reg. No. 45,220
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Date: January 6, 2004

Use the following customer number for all correspondence regarding this application.

23650
PATENT TRADEMARK OFFICE